

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of Earliest Event Reported): May 2, 2018**

---

**Proteostasis Therapeutics, Inc.**  
(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-37695**  
(Commission  
File Number)

**20-8436652**  
(I.R.S. Employer  
Identification No.)

**80 Guest Street, 5th Floor**  
**Boston, MA**  
(Address of principal executive offices)

**02135**  
(Zip Code)

**Registrant's telephone number, including area code (617) 225-0096**

**200 Technology Square, 4th Floor, Cambridge, MA 02139**  
(Former name or former address, if changed since last report)

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

(b) On May 2, 2018, Proteostasis Therapeutics, Inc.'s Chief Financial Officer and Treasurer, Helen Boudreau, provided notice of her resignation from the Company to pursue another professional opportunity. Ms. Boudreau will remain the CFO and Treasurer through June 1, 2018. The Company has commenced a search for a replacement.

**Item 8.01 Other Events.**

The Company incorporates by reference into this Item 8.01 the information contained in Item 5.02 of this Current Report on Form 8-K.

